Why do we need observational studies of everyday patients in the real-life setting?

被引:106
作者
Cohen, Alexander T. [1 ]
Goto, Shinya [2 ]
Schreiber, Karen [1 ,3 ]
Torp-Pedersen, Christian [4 ]
机构
[1] Kings Coll London, Guys & St Thomas NHS Fdn Trust, Dept Haematol Med, London SE1 7EH, England
[2] Tokai Univ, Inst Med Sci, Hiratsuka, Kanagawa 25912, Japan
[3] Rigshosp, Copenhagen Univ Hosp, Dept Rheumatol, DK-2100 Copenhagen, Denmark
[4] Aalborg Univ, Aalborg, Denmark
关键词
Clinical trials; Real-life studies; Efficacy; Effectiveness; Safety; Special populations; Randomized controlled trials; ATRIAL-FIBRILLATION; ORAL ANTICOAGULANTS; VENOUS THROMBOEMBOLISM; RISK; PREVENTION; WARFARIN; STROKE; DABIGATRAN; REGISTRY; THERAPY;
D O I
10.1093/eurheartj/suv035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Randomized controlled trials (RCTs) are performed with the primary goal of understanding the safety and efficacy of a new therapy in a selected group of patients. Even when evidence from these studies strongly favours a new therapy, its role in routine clinical practice may be unclear because of the considerable differences between its efficacy (in clinical trials) and its effectiveness (in the real-life setting). Real-life studies are observational studies that are essential to document benefits and harms of therapy in a wider population and to determine whether patients in routine practice are achieving expected outcomes. In the first article of this supplement, we discuss the relative strengths and limitations of RCTs and real-life studies and explore the current and potential uses of real-life studies in the field of thrombosis, including identifying new safety signals, assessing outcomes in special populations and raising questions about factors affecting medication adherence and persistence. Real-life studies provide a bridge from the results of RCTs to daily clinical practice.
引用
收藏
页码:D2 / D8
页数:7
相关论文
共 63 条
[1]  
Agnelli G, 2014, EUR HEART J, V35, P1002
[2]   Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry [J].
Akao, Masaharu ;
Chun, Yeong-Hwa ;
Wada, Hiromichi ;
Esato, Masahiro ;
Hashimoto, Tetsuo ;
Abe, Mitsuru ;
Hasegawa, Koji ;
Tsuji, Hikari ;
Furuke, Keizo .
JOURNAL OF CARDIOLOGY, 2013, 61 (3-4) :260-266
[3]  
Andersen TF, 1999, DAN MED BULL, V46, P263
[4]   Risk factors for venous thromboembolism [J].
Anderson, FA ;
Spencer, FA .
CIRCULATION, 2003, 107 :I9-I16
[5]  
Annemans L., 2007, Real-Life Data: A Growing Need
[6]   New oral anticoagulants in elderly patients [J].
Barco, Stefano ;
Cheung, Yuk Wah ;
Eikelboom, John W. ;
Coppens, Michiel .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (02) :215-224
[7]   Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans [J].
Bathala, Mohinder S. ;
Masumoto, Hiroshi ;
Oguma, Toshihiro ;
He, Ling ;
Lowrie, Chris ;
Mendell, Jeanne .
DRUG METABOLISM AND DISPOSITION, 2012, 40 (12) :2250-2255
[8]   Oral Rivaroxaban for Symptomatic Venous Thromboembolism. [J].
Bauersachs, Rupert ;
Berkowitz, Scott D. ;
Brenner, Benjamin ;
Buller, Harry R. ;
Decousus, Herve ;
Gallus, Alex S. ;
Lensing, Anthonie W. ;
Misselwitz, Frank ;
Prins, Martin H. ;
Raskob, Gary E. ;
Segers, Annelise ;
Verhamme, Peter ;
Wells, Phil ;
Agnelli, Giancarlo ;
Bounameaux, Henri ;
Cohen, Alexander ;
Davidson, Bruce L. ;
Piovella, Franco ;
Schellong, Sebastian .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) :2499-2510
[9]  
Bayer Pharma AG, XAR SUMM PROD CHAR
[10]   Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry [J].
Beyer-Westendorf, Jan ;
Gelbricht, Vera ;
Foerster, Kati ;
Ebertz, Franziska ;
Koehler, Christina ;
Werth, Sebastian ;
Kuhlisch, Eberhard ;
Stange, Thoralf ;
Thieme, Christoph ;
Daschkow, Katharina ;
Weiss, Norbert .
EUROPEAN HEART JOURNAL, 2014, 35 (28) :1888-1896